We report outcomes of Bv‐ICE in CD30 (+) and Ro‐ICE in CD30 (−) R/R PTCL treated in “Blinded for peer review” Cancer Center. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.